AI Summary
This study focuses on the use of Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, after definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small-cell lung cancer. The research analyzes the drug's efficacy in preventing distant progression, particularly in the central nervous system, in NSCLC patients. The LAURA study shows promising results in improving progression-free survival compared to a placebo in this patient population.
Distant metastases in non-small-cell lung cancer (NSCLC) are a poor prognostic factor that negatively impact quality of life. The central nervous system (CNS) is a common site of distant progression in epidermal growth factor receptor-mutated (EGFRm) NSCLC. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor recommended for advanced EGFRm NSCLC and as adjuvant treatment for resected EGFRm NSCLC. In LAURA (NCT03521154), osimertinib demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in unresectable stage III EGFRm NSCLC without progression during/following chemoradiotherapy (CRT).